As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

The STATUS Trial

Clinical Trial Title: 
The STATUS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAGE-547 injection in the treatment of subjects with super-refractory status epilepticus (SRSE).
Clinical Trial Protocol ID: 
15032003
Clinical Trial Investigator Name: 
Sebastian Pollandt, MD
Clinical Trial Protocol Description: 

The purpose of this study is to evaluate the efficacy and safety of an investigational medicine compared to placebo for the treatment of super-refractory status epilepticus. This is a multicenter trial seeking to recruit 140 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have failed to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial AED treatment).
  • Have failed to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED.

You will be excluded from the study if any of the following criteria apply to you:

  • Have certain medical conditions.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Epilepsy
Contact Phone: 
(312) 563-2741
Contact Name: 
Raquel Garcia-Cano